Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
According to WHO, over 1.5 million people died of TB in 2020
Subscribe To Our Newsletter & Stay Updated
